TYRA Tyra Biosciences, Inc.

8-K Current Report

Filed: March 2, 2026

Health Care

Pharmaceutical Preparations

Tyra Biosciences, Inc. (TYRA) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Full-year 2025 financial results reported; press release (Exhibit 99.1) contains key figures including cash, R&D spend, and net loss
• Filing date March 2, 2026; results cover fiscal year ended December 31, 2025

+1 more insights

Other Tyra Biosciences, Inc. 8-K Filings

8-K Mar 4, 2026

Get deeper insights on Tyra Biosciences, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.